What is the trajectory of viral load dynamics & test sensitivity post-INFECTION?

We're 17 month into the pandemic &, shockingly, this Q is still only partly answered.
Recent paper using a study design I proposed 12 months ago provides detailed look & raises many questions.
Background
We know that ~3-6d following infection COVID-19 symptoms start (the incubation period). doi:10.1136/
bmjopen-2020-039652
We also know that people are infectious before symptom onset - this has been one of the greatest challenges in controlling SARS-CoV-2.
In fact, we even know some details: we know that the longer the incubation period the longer the pre-symptomatic infectious period. Fig from our work w/ @LucaFerrettiEvo @ChrisWymant @ChristoPhraser @mishkendall @JoannaMasel doi.org/10.1101/2020.0…
However, the detailed dynamics of viral loads before symptom onset are still poorly known, despite their importance. Meta-analyses of viral loads or test sensitivity are data-rich starting at symptom onset (Fig), but very data-poor before. @bennyborremans doi.org/10.7554/eLife.…
Here's another paper on test sensitivity. Note extreme sparsity of data before symptom onset.
sciencedirect.com/science/articl…
Here's a meta-analysis of viral loads. Note the wide CI before 0 due to sparse data.
doi.org/10.1101/2020.0… @BMAlthouse
But wait: some of you may know of great NBA paper that had detailed viral loads from frequent swabbing. Unfortunately, this study didn't have the date of infection or day of symptom onset. @yhgrad @StephenKissler
doi.org/10.1101/2020.1…
As a result, they modeled a theoretical viral load trajectory, but couldn't scale it to time since infection or symptom onset.
You may be wondering, if we know the infectiousness pattern vs time since infection, why do the viral loads it matter? Many reasons, but the most important is because they determine test sensitivity over time. I've been writing about this since June 2020:
Testing is still being used to screen people for travel, entry into events, schools, etc. Thus it's crucial to know how good tests are at finding infected people vs time since infection.
Here's an attempt to gather data on viral loads & live virus to estimate the infectious period from June 2020:

In October 2020 I again lamented lack of pre-symptom onset data:

& an article @sarahzhang theatlantic.com/science/archiv…
Lots of theory on how test sensitivity determines the effectiveness of frequent testing to reduce transmission. Most papers have used models like this of viral loads. DOI: 10.1126/sciadv.abd5393
@DanLarremore @michaelmina_lab
DOI: 10.1056/NEJMp2025631
But none of these papers have viral load data on the rise in viral loads relative to days since exposure & symptom onset. They simply don't exist. But why? The study design to collect these data is pretty simple. I laid it out in detail June 8, 2020:
In short: Collect daily swabs from recent close contacts of cases over time, and keep swabbing after initial detection until virus is no longer detectable. Unfortunately I never saw a paper that used this approach. Until today! (h/t @profshanecrotty)
Here's the paper:
medrxiv.org/content/10.110…
Here's the amazing data. Twice (!) daily nasal (NOT NP) swabs & saliva, detailed 2x daily symptom diary & human DNA as control for swab/saliva quality. Absolutely fantastic. Unfortunately, 1 giant caveat: only N=4 people in study. Despite this, many interesting patterns & Qs.
1st: substantial differences in saliva vs nasal swab viral load trajectories (one is not always higher than the other). Virus detected in saliva 1st, 1-5d earlier than nasal swabs, but most nasal load swabs much higher than saliva for 3/4 people. What produces these patterns?
2nd: Long (5.5d) period of virus detected in saliva but not nasal swab, for 1 person (young child). Is this common in children?
3: Highly variable symptoms w/ patchy onset relative to viral loads. Makes symptom checks challenging!
4: viral loads almost always higher in morning than at night (noted by @profshanecrotty). Why is this? Because person was laying down before sampling? Does this increase infectiousness or just test sensitivity?
5: Paper argues saliva is better than nasal swabs (+s earlier) but it requires high sensitivity test to detect virus. Many saliva samples were below rapid test detection limit (green shading, dashed line). Thus paper argues against using less sensitive rapid tests .
But as @michaelmina_lab has tirelessly argued, rapid test done daily would catch people when infectious & would be preferable unless sensitive PCR could also be done daily & return results quickly (w/in 24 hrs).
Also, it's not clear if low-moderate saliva load is infectious.
Are there data comparing viral loads in saliva vs loads in nasal swabs in predicting secondary attack rates (e.g. )? I haven't seen a study doing so but it would be useful to answer question of whether moderate saliva loads imply infectiousness.
Also, although paper argues saliva is better, saliva testing here required sampling at least 30 min after any eating/drinking which is difficult to implement in general population.
Summary: Lots of cool patterns & unanswered Qs. We need this kind of data for a few more dozen more people of varying ages. I hope this study will be replicated soon!

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with A Marm Kilpatrick

A Marm Kilpatrick Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @DiseaseEcology

21 May
How effective are vaccines vs severe & all disease, death, infection, & transmission?
Very nice collection of studies assessing different aspects of vaccine protection by Julia Shapiro (on twitter?) @nataliexdean @betzhallo @ilongini & 2 others.
Thread
medrxiv.org/content/10.110…
Study has data on many different measures of protection:
all infection (symp + asymp), all symptomatic (mild+severe), severe, hospitalization, death, & transmission,
for 8 vaccines: Moderna, Pfizer, Novavax, Astrazeneca, Sinopharm, Sinovac, Sputnik, J&J,
3 variants&
1&2 doses
For those wanting to understand relationships among different vaccine efficacy measures more, recent preprint @mlipsitch @kahnrebecca, lays it out nicely. doi.org/10.1101/2021.0…;
Read 17 tweets
20 May
Should vaccinated people stop wearing masks?
Happy to contribute to article @B_resnick w @MonicaGandhi9 @AbraarKaran @DocJeffD @DrJeanneM
Short thread w/ my perspective on how to navigate CDC guidance on masks post-vaccination.

vox.com/science-and-he…
1st: Protection from vaccination is NOT 100% (no surprise to anyone that follows me to hear this)
So, despite being vaccinated, I'm still going to wear a mask in what I consider high(er) risk situations - indoors w/ dozens of households, unless community transmission is VERY low.
What is very low? My perspective: CA (where I live) has tiers based on daily cases/100K. Lowest tier is <2/100K. If we assume there are 5 infections/case & people are infectious for 10d, this translates to 1/1K. Pretty low. If everyone is vaccinated, risk ~10x+ lower so <1/10K.
Read 11 tweets
4 May
Interesting thread @trvrb on growth of B.1.1.7, P.1, B.1.351 in US
I worry about key assumptions underlying these analyses:
-sequences are random sample of state/US infections (definitely not)
-trends in sequences represent local transmission rather than changes in imported cases
Many of the P.1, B.1.351 numbers are very low & introduced cases can make a substantial contribution to total count. Increased transmission elsewhere (e.g. Europe, S America) & constant introductions can lead to apparent increase in US for foreign variants.
In addition, increased detection of introduced cases can also bias results towards observing a local increase of an introduced variant.
Are cases (not frequencies) of P.1 really increasing in many states as @trvrb suggests? Possibly.
Read 6 tweets
13 Apr
Vaccination can have rapid impacts on transmission & disease & surging vaccines to MI could save many lives.
Comments in NYT article from multiple health officials including @CDCDirector @celinegounder are surprisingly at odds w/ data. 1-2 wks not 6. nytimes.com/2021/04/12/us/…
@CDCDirector argues increasing vaccine supply to MI would take 6 weeks to take effect.
Article by @noahweiland @MitchKSmith tries to explain this by stating that time for full protection w/ mRNA vaccines. But we know 1 dose offers substantial protection vs disease AND infection.
Paper published in CDC's own journal MMWR showed protection against INFECTION (not symptoms) is 80% 2 wks after 1st dose. Thus, vaccinating people could reduce transmission much more quickly than 6 wks.
cdc.gov/mmwr/volumes/7…
Read 6 tweets
30 Mar
Why have we given up on targeted vaccination & dose sparing?

Many announcements like below. Seems great except most 50y+ aren't vaccinated in most states, nor are those w/ pre-existing conditions. Given surging cases & still limited vaccines this will lead to avoidable deaths.
In case folks have forgotten death is huge age-dependent (). It's ~10x higher for every 20 yrs of age. Same for hospitalizations. And yet most states are open to 16/18+ (nytimes.com/interactive/20…).
Remember all the discussions about ways to vaccinate faster? Half-doses? Large gap b/w doses? 0/1 doses initially for already infected? Now clear strong evidence for all these strategies, & yet...
silence.
Read 7 tweets
26 Mar
Differential growth trajectories of B.1.1.7 (UK variant) in US states.

The rate of increase in frequency of B.1.1.7 varies between different locations that also differ in case trajectories. What is driving this?

Thread
We know have clear evidence of variant B.1.1.7 being more 50-100% infectious & ~67% more deadly. It is likely playing an important role in the current surge in cases in Europe.
nature.com/articles/s4158…
doi.org/10.2807/1560-7…
B.1.1.7 has also been detected in many US states(helix.com/pages/helix-co…) & is probably present in most states now. In Jan-Feb most expected it to spread rapidly in US to become the dominant variant like it did in UK Nov-Jan, & other EU countries later (nature.com/articles/s4158…)
Read 18 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!

:(